SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Sold by Rehmann Capital Advisory Group

Rehmann Capital Advisory Group lessened its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 98.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 943 shares of the exchange traded fund’s stock after selling 74,454 shares during the quarter. Rehmann Capital Advisory Group’s holdings in SPDR S&P Biotech ETF were worth $85,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of XBI. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of SPDR S&P Biotech ETF by 15.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,635 shares of the exchange traded fund’s stock valued at $601,000 after purchasing an additional 900 shares in the last quarter. Tocqueville Asset Management L.P. raised its stake in shares of SPDR S&P Biotech ETF by 65.1% during the 4th quarter. Tocqueville Asset Management L.P. now owns 149,590 shares of the exchange traded fund’s stock worth $10,733,000 after acquiring an additional 58,960 shares in the last quarter. Foresters Investment Management Company Inc. raised its stake in shares of SPDR S&P Biotech ETF by 22.1% during the 4th quarter. Foresters Investment Management Company Inc. now owns 63,500 shares of the exchange traded fund’s stock worth $4,556,000 after acquiring an additional 11,500 shares in the last quarter. MML Investors Services LLC raised its stake in shares of SPDR S&P Biotech ETF by 31.0% during the 4th quarter. MML Investors Services LLC now owns 61,171 shares of the exchange traded fund’s stock worth $4,389,000 after acquiring an additional 14,466 shares in the last quarter. Finally, Means Investment CO. Inc. raised its stake in shares of SPDR S&P Biotech ETF by 12.9% during the 1st quarter. Means Investment CO. Inc. now owns 61,632 shares of the exchange traded fund’s stock worth $5,580,000 after acquiring an additional 7,060 shares in the last quarter.

Shares of NYSEARCA XBI traded down $0.12 during trading hours on Friday, hitting $85.82. 3,681,563 shares of the stock were exchanged, compared to its average volume of 4,806,214. SPDR S&P Biotech ETF has a 12 month low of $64.38 and a 12 month high of $101.06. The firm’s fifty day simple moving average is $84.39.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Read More: Net Margin – Understanding the Different Kinds of Profit

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.